verezdoBulletin of Reproductive HealthВестник репродуктивного здоровья2075-65692310-421XEndocrinology Research Centre (Moscow)10.14341/brh2011116-21verezdo-8560Research ArticleArticlesСтатьиHyperprolactinemia and pregnancy: the basic achievements and unresolved problemsГиперпролактинемия и беременность: основные достижения и нерешенные вопросыДзерановаЛ КDzeranovaL Kmetabol@endocrincentr.ruБыкановаН СBykanovaN Smetabol@endocrincentr.ruПигароваЕ АPigarovaE Akpigarova@gmail.com<p>ФГУ Эндокринологический научный центр</p><p>Endocrinology Research Centre, Moscow, Russia</p>20111703201101NO1 (2011)1621Copyright &#x00A9; Dzeranova L.K., Bykanova N.S., Pigarova E.A., 20112011Дзеранова Л.К., Быканова Н.С., Пигарова Е.А.Dzeranova L.K., Bykanova N.S., Pigarova E.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vrz-endojournals.ru/jour/article/view/8560

From the sociopolitical and economic points of view the child-bearing is very actual problem for Russia. Demographers believe that our population can decrease twice in 25-30 years, because of medical factors partly.Every fifth family in Russia is infertility now. Female infertility is caused by hyperprolactinemia in 25-40 % of all cases. Rate of hyperprolactinemia at the infertile men reaches 30 %. However hyperprolactinemia is the cause of infertility which can be successfully cured now.

Курсив

Курсив

Жирный

Жирный

Обычный нижний верхний

Обычный нижний верхний

В настоящее время проблема деторождения очень актуальна для России как с социально-политической, так и с экономической точек зрения. По прогнозам демографов, через 25-30 лет численность нашего населения может уменьшиться в 2 раза, и в этом есть доля вины медицинских факторов.На сегодняшний день в России каждая пятая семья является бесплодной. До 25-40% всех случаев женского бесплодия обусловлено гиперпродукцией пролактина. Частота гиперпролактинемии у мужчин, страдающих бесплодием, достигает 30%. При этом гиперпролактинемия это та причина бесплодия, которая в современных условиях может быть успешно устранена.

гиперпролактинемиябесплодиебеременностьпролактиномакаберголинсabergolinehyperprolactinemiainfertilitypregnancyprolactinoma

Курсив

Жирный

Обычный нижний верхний

ReferencesМарова Е И Вакс В В Дзеранова Л К Гиперпролактинемия у женщин и мужчин Пособие для врачей М Pharmacia Upjohn 2000Марова Е И Вакс В В Дзеранова Л К Гиперпролактинемия у женщин и мужчин Пособие для врачей М Pharmacia Upjohn 2000Дедов И И Мельниченко Г А Романцова Т И Синдром гиперпролактинемии М Тверь Триада, 2004Дедов И И Мельниченко Г А Романцова Т И Синдром гиперпролактинемии М Тверь Триада, 2004Романцова Т И Особенности клинической симптоматики диагностики и лечения синдрома гиперпролактинемии у женщин Дисс д ра мед наук М. 2001Романцова Т И Особенности клинической симптоматики диагностики и лечения синдрома гиперпролактинемии у женщин Дисс д ра мед наук М. 2001Дзеранова Л К Синдром гиперпролактинемии у женщин и мужчин клиника диагностика лечение Дисс д ра мед наук М 2007.Дзеранова Л К Синдром гиперпролактинемии у женщин и мужчин клиника диагностика лечение Дисс д ра мед наук М 2007.GillamMP MolitchME LombardiG Colao A Advances in the treatment of prolactinomas Endocr Rev 2006 27: 485 534GillamMP MolitchME LombardiG Colao A Advances in the treatment of prolactinomas Endocr Rev 2006 27: 485 534Casanueva FF, Molitch ME, Schlechte JA et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas Clin Endocrin 2006 65: 265 273.Casanueva FF, Molitch ME, Schlechte JA et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas Clin Endocrin 2006 65: 265 273.Webster J, Piscitelli G, Polli A et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea N Engl J Med 1994 331: 904 909.Webster J, Piscitelli G, Polli A et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea N Engl J Med 1994 331: 904 909.Swearingen B, Biller BMK. Diagnosis and Management of Pituitary Disorders Humana Press 2008Swearingen B, Biller BMK. Diagnosis and Management of Pituitary Disorders Humana Press 2008Casanueva FF Molitch ME Schlechte JA et al Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas Clin Endocrin 2006 65: 265 273Casanueva FF Molitch ME Schlechte JA et al Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas Clin Endocrin 2006 65: 265 273Central Brain Tumor Registry of the United States (CTBRUS). Statistical Report. Primary brain tumors in the US 1997 2001 http://www.cbtrus.org/. Accessed April 8, 2005.Central Brain Tumor Registry of the United States (CTBRUS). Statistical Report. Primary brain tumors in the US 1997 2001 http://www.cbtrus.org/. Accessed April 8, 2005.Goluboff LG, Ezrin C Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis J Clin Endocrin Metab 1969 29: 1533 1538.Goluboff LG, Ezrin C Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis J Clin Endocrin Metab 1969 29: 1533 1538.Scheithauer BW, Sano T, Kovacs KT et al. The pituitary gland in pregnancy. A clinicopathologic and immunohistochemical study of 69 Cases Mayo Clin Proc 1990 65: 461 474.Scheithauer BW, Sano T, Kovacs KT et al. The pituitary gland in pregnancy. A clinicopathologic and immunohistochemical study of 69 Cases Mayo Clin Proc 1990 65: 461 474.Rigg LA, Lein A, Yen SSC Pattern of increase in circulating prolactin levels during human gestation Am J Obstet Gyn 1977 129: 454 456.Rigg LA, Lein A, Yen SSC Pattern of increase in circulating prolactin levels during human gestation Am J Obstet Gyn 1977 129: 454 456.Gonzalez JG, Elizondo G, Saldivar D et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging Am J Med 1988 85: 217 220.Gonzalez JG, Elizondo G, Saldivar D et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging Am J Med 1988 85: 217 220.Elster AD, Sanders TG, Vines FS et al. Size and shape of the pituitary gland during pregnancy and post partum: Measurement with MR imaging Radiology 1991 181: 531 535.Elster AD, Sanders TG, Vines FS et al. Size and shape of the pituitary gland during pregnancy and post partum: Measurement with MR imaging Radiology 1991 181: 531 535.Ricci E, Parazzini F, Motta T et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation Reproduct Toxicol 2002 16:791 793Ricci E, Parazzini F, Motta T et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation Reproduct Toxicol 2002 16:791 793Ono M, Miki N, Amano K et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas J Clin Endocrin Metab 2010 95: 2672 2679Ono M, Miki N, Amano K et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas J Clin Endocrin Metab 2010 95: 2672 2679Molitch ME Pituitary disorders during pregnancy Endocrin Metabol Clin NorthAm2006 35 99 116.Molitch ME Pituitary disorders during pregnancy Endocrin Metabol Clin NorthAm2006 35 99 116.Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Ann Internal Med 1994 121: 473 477.Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Ann Internal Med 1994 121: 473 477.Molitch ME. Pregnancy and the hyperprolactinemic woman New Engl J Med 1985 312 1364 1370.Molitch ME. Pregnancy and the hyperprolactinemic woman New Engl J Med 1985 312 1364 1370.Molitch ME Management of prolactinomas during pregnancy J Reprod Med 1999 44(12): 1121 1126Molitch ME Management of prolactinomas during pregnancy J Reprod Med 1999 44(12): 1121 1126Bronstein MD, Salgado LR, Musolino NR. Medical management of pituitary adenomas: The special case of the pregnant woman Pituitary 2002 5: 99 107.Bronstein MD, Salgado LR, Musolino NR. Medical management of pituitary adenomas: The special case of the pregnant woman Pituitary 2002 5: 99 107.Moore WT, Eastman RC. Diagnostic Endocrinology. Acromegaly prolactin and gonadotropin secreting ademomas hypopituitaris Philadelphia, Decker 1996Moore WT, Eastman RC. Diagnostic Endocrinology. Acromegaly prolactin and gonadotropin secreting ademomas hypopituitaris Philadelphia, Decker 1996Cohen-Kerem R, Railton C, Orfen D et al. Pregnancy outcome following non-obstetric surgical intervention Am J Surg 2005 190 467 473.Cohen-Kerem R, Railton C, Orfen D et al. Pregnancy outcome following non-obstetric surgical intervention Am J Surg 2005 190 467 473.Lebbe M, Hubinont C, Bernard P, Maiter D.Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women Clin Endocrin (Oxf) 2010 73(2):236-42Lebbe M, Hubinont C, Bernard P, Maiter D.Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women Clin Endocrin (Oxf) 2010 73(2):236-42Davis JR, Farrell WE, Clayton RN. Pituitary tumours Reproduction 2001 121(3): 363-371.Davis JR, Farrell WE, Clayton RN. Pituitary tumours Reproduction 2001 121(3): 363-371.Jeffcoate WJ, Pound N, Sturrock ND et al. Long-term follow-up of patients with hyperprolactinaemia Clin Endocrin 1996 45 299 303.Jeffcoate WJ, Pound N, Sturrock ND et al. Long-term follow-up of patients with hyperprolactinaemia Clin Endocrin 1996 45 299 303.28.Divers WA, Yen SSC Prolactin-producing microadenomas in pregnancy Obstet Gyn 1983 62: 425 429.28.Divers WA, Yen SSC Prolactin-producing microadenomas in pregnancy Obstet Gyn 1983 62: 425 429.Krupp P Monka C. Bromocriptine in pregnancy: safety aspects KlinischeWochenschrift 1987 65 823 827.Krupp P Monka C. Bromocriptine in pregnancy: safety aspects KlinischeWochenschrift 1987 65 823 827.Krupp P, Monka C, Richter K. The safety aspects of infertility treatments Program of the Second World Congress of Gynecology and Obstetrics, Rio de Janeiro, October, 1988.Krupp P, Monka C, Richter K. The safety aspects of infertility treatments Program of the Second World Congress of Gynecology and Obstetrics, Rio de Janeiro, October, 1988.Robert E, Musatti L, Piscitelli G еt al. Pregnancy outcome after treatment with the ergot derivative, cabergoline Reprod Toxicol 1996 10: 333 337Robert E, Musatti L, Piscitelli G еt al. Pregnancy outcome after treatment with the ergot derivative, cabergoline Reprod Toxicol 1996 10: 333 337Colao A, Abs R, Gonzalez Ba rcena Dеt al. Pregnancy outcomes following cabergoline treatment: extended results from a 12- year observational study Clin Endocrin (Oxf) 2008 68(1): 66 71Colao A, Abs R, Gonzalez Ba rcena Dеt al. Pregnancy outcomes following cabergoline treatment: extended results from a 12- year observational study Clin Endocrin (Oxf) 2008 68(1): 66 71StalldeckerG Mallea-Gil MS GuitelmanMet al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature Pituitary 2010 13(4): 345-350.StalldeckerG Mallea-Gil MS GuitelmanMet al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature Pituitary 2010 13(4): 345-350.Nybo Andersen AM, Wohlfahrt J, Christens P et al. Maternal age fetal loss: population based register linkage study BMJ2000 320: 1708 1712Nybo Andersen AM, Wohlfahrt J, Christens P et al. Maternal age fetal loss: population based register linkage study BMJ2000 320: 1708 1712Окороков А Н Гиперпролактинемический синдром Диагностика болезней внутренних органов М Мед лит 2001.Окороков А Н Гиперпролактинемический синдром Диагностика болезней внутренних органов М Мед лит 2001.Abech DD Moratelli HB Leite SC Oliveira MC. Effects of estrogen replacement therapy on pituitary size, prolactin and thyroid-stimulating hormone concentrations in menopausal women Gyn Endocrin 2005 21(4): 223-236.Abech DD Moratelli HB Leite SC Oliveira MC. Effects of estrogen replacement therapy on pituitary size, prolactin and thyroid-stimulating hormone concentrations in menopausal women Gyn Endocrin 2005 21(4): 223-236.Banerjee A, Wynne K, Tan T et al. High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy Clin Endocrin (Oxf) 2009 70(5): 812 813.Banerjee A, Wynne K, Tan T et al. High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy Clin Endocrin (Oxf) 2009 70(5): 812 813.Morange I, Barlier A, Pellegrini I et al. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy Eur J Endocrin 1996 135: 413 420.Morange I, Barlier A, Pellegrini I et al. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy Eur J Endocrin 1996 135: 413 420.Molitch ME. Prolactinomas and pregnancy Clin Endocrin 2010 73 147 148Molitch ME. Prolactinomas and pregnancy Clin Endocrin 2010 73 147 148

The authors declare that there are no conflicts of interest present.